Lisaftoclax yet another and seemingly better drug

[Research123]

cancernetwork.com/view/earl...

I do find it encouraging that every few months there is another breakthrough. This seems to be better tolerated than venetoclax so hopefully will be available to all in the not too distant future

[Jm954 Administrator]

Interesting, thank you

[CLLerinOz Administrator]

Thanks for posting about this.

There's some additional information about Lisaftoclax in this post:

healthunlocked.com/cllsuppo...

'During the 2021 ASCO Annual Meeting, findings from a first-in-human study of the novel BCL-2 inhibitor lisaftoclax were presented, demonstrating an 80% overall response rate in patients with relapsed/refractory CLL and small lymphocytic lymphoma.'

'Notably, no cases of laboratory or clinical tumor lysis syndrome were observed with lisaftoclax' suggesting that 'it could offer patients a novel treatment approach that doesn’t require hospitalization or slow dose-escalation'.

onclive.com/view/dr-ailawad...